BPC-157_Dosage, benefits & legal status

Guides for this compound

• How to Reconstitute a Peptide

  Mix peptide powder with bacteriostatic water, step by step.

• How to Read an Insulin Syringe

  Read the units, convert to millilitres, and draw the exact dose.

• mcg vs mg: The Peptide Dosing Mistake to Avoid

  Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.

• BPC-157 and TB-500: What the Healing Pair Actually Is

  They are different molecules, taken on different schedules, and one of them is not the molecule its research belongs to.

• How to Read a Peptide COA

  What the purity number does and does not tell you, and how to spot an edited report.

Sources

• FDA, bulk substances that may present significant safety risks(2026)
  FDA states that compounded drugs containing BPC-157 may pose a risk of immunogenicity for certain routes, that there are complexities around peptide-related impurities and characterising the active ingredient, and that it has identified no or only limited safety information for the proposed routes, so it cannot know whether the drug would cause harm in people. BPC-157 was placed in 503A category 2 on 29 September 2023. As of the 22 April 2026 version of this page, the substance sits in the second table, headed bulk drug substances nominated but withdrawn, rather than in the live category 2 list. The nomination was withdrawn, which is not the same as being approved or cleared: FDA still publishes the safety language above, and no longer has a nomination in front of it to evaluate.
• FDA, bulk drug substances used in compounding under 503A(2026)
  Defines what the categories mean. Category 2 is a judgement about safety risk pending evaluation, and it governs whether a pharmacy may compound the substance. It is not a finding that a substance does or does not work. The page also records that FDA does not intend to place substances nominated on or after 7 January 2025 into these categories at all, so a newer compound's absence from the list means nothing either way.
• Rat tendon-to-bone study, PubMed, 2006
• Tendon fibroblast mechanism, Journal of Applied Physiology
• FDA, Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026(2026)
  FDA put BPC-157 in front of its Pharmacy Compounding Advisory Committee on 23 July 2026, to decide whether it should go on the 503A bulks list and become usable in compounded medicines. Note the use FDA actually evaluated: ulcerative colitis. Not tendon repair, not gut-lining healing in general, not any of the injury and recovery claims the compound is sold on. A regulator assessing a narrow inflammatory bowel indication is a different question from whether BPC-157 does what a vendor page says it does. Two things about the page itself. It sets out the agenda and links FDA's briefing document for each substance, but it does not record how the vote went, so it tells you what was assessed rather than what was decided. And the page notes that advisory committees give non-binding recommendations which FDA generally follows but is not legally bound to, so even the vote would not be the final word.
• FDA briefing document, BPC-157-related bulk drug substances(2026)
  FDA's own 68-page evaluation, and the most complete assessment of BPC-157 that exists. Start with what was left out. BPC-157 was nominated for ulcerative colitis, Crohn's, celiac disease and tendonitis, and FDA evaluated only ulcerative colitis, stating that the other uses lacked sufficient information and that it identified no clinical studies of BPC-157 in those populations. The injury-repair use this entire market runs on was not assessed because there was nothing to assess. On the use FDA did evaluate, the whole human efficacy case is a single conference abstract from 2005: 53 subjects, an 80 mg rectal enema daily for two weeks, disease activity falling 3.2 points on BPC-157 against 1.6 on placebo, with the between-group difference of 1.6 points carrying a confidence interval from minus 4.84 to 1.62. That interval crosses zero, and the study was never published in full. Across all five human studies FDA found, involving at most a couple of dozen people each, no serious adverse events were reported, but no human pharmacokinetic data exist either, and BPC-157 was not detected in plasma after rectal dosing at all. In animals the intravenous half-life is 5.3 minutes in dogs and 15.2 minutes in rats. The safety findings are specific rather than vague: 28 days of intramuscular dosing in rats and dogs altered clotting times, shortened in rats and prolonged in dogs, and raised ALT, glucose and triglycerides, which FDA describes as clinically relevant signals. There is no carcinogenicity study. More reassuringly, BPC-157 was not mutagenic in three assays and not teratogenic in rats. No country has approved any BPC-157 product, it appears in no major pharmacopoeia, and neither the American College of Gastroenterology nor the AGA guidelines mention it. FDA proposed not adding it to the 503A bulks list.

Last reviewed 14 August 2026

Beyond these, 234 records are indexed. Browse the records